Company news

Immuneering Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer

November 18, 2026

Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer

November 18, 2026

Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer

November 12, 2026

Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients

November 12, 2026

Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors

November 9, 2026

Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026

November 6, 2026

Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

November 4, 2026

Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium

November 4, 2026

Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates

October 29, 2026

Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026

October 26, 2026

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

October 2, 2026

Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer

September 28, 2026

Immuneering to Present at the ESMO Congress 2026

September 24, 2026

Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival

September 10, 2026

Immuneering to Participate in Upcoming Investor Conferences

September 3, 2026

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

August 26, 2026

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 5, 2026

Immuneering Corporation Announces Grants of Inducement Awards

July 17, 2026

Immuneering Appoints Andrew Gengos as Chief Financial Officer

June 15, 2026

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

June 11, 2026

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

June 1, 2026

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

May 21, 2026

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

May 15, 2026

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

April 21, 2026

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

April 20, 2026

Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference

April 6, 2026

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

March 17, 2026

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

March 6, 2026

Immuneering to Present at the Leerink Global Healthcare Conference

March 2, 2026

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 18, 2026

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

January 7, 2026

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

December 23, 2025

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

December 17, 2025

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

December 16, 2025

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

November 25, 2025

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

November 12, 2025

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

November 4, 2025

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

September 26, 2025

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

September 25, 2025

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

September 24, 2025

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

September 24, 2025

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

September 16, 2025

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

September 10, 2025

Immuneering Announces Closing of $25 Million Private Placement

August 26, 2025

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

August 25, 2025

Immuneering Announces $25 Million Private Placement

August 21, 2025

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 13, 2025

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

July 9, 2025

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

June 17, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

June 16, 2025

Older news releases →

Calls

Decks